- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.72 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x ZN: ZINC ION(Non-covalent)
- 4 x MG: MAGNESIUM ION(Non-covalent)
MG.2: 2 residues within 4Å:- Chain A: D.123
- Ligands: ZN.1
6 PLIP interactions:1 interactions with chain A, 5 Ligand-Water interactions- Metal complexes: A:D.123, H2O.5, H2O.7, H2O.14, H2O.14, H2O.15
MG.5: 2 residues within 4Å:- Chain B: D.123
- Ligands: ZN.4
6 PLIP interactions:1 interactions with chain B, 5 Ligand-Water interactions- Metal complexes: B:D.123, H2O.22, H2O.28, H2O.29, H2O.29, H2O.29
MG.8: 3 residues within 4Å:- Chain C: D.123, H.156
- Ligands: ZN.7
6 PLIP interactions:1 interactions with chain C, 5 Ligand-Water interactions- Metal complexes: C:D.123, H2O.30, H2O.41, H2O.41, H2O.41, H2O.42
MG.11: 2 residues within 4Å:- Chain D: D.123
- Ligands: ZN.10
6 PLIP interactions:1 interactions with chain D, 5 Ligand-Water interactions- Metal complexes: D:D.123, H2O.45, H2O.54, H2O.55, H2O.55, H2O.56
- 4 x 1L6: 1-(2-hydroxyethyl)-3-(2-methylbutan-2-yl)-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(1H)-one(Non-covalent)
1L6.3: 14 residues within 4Å:- Chain A: Y.81, L.196, L.235, D.237, Q.238, I.248, I.252, Y.253, F.256, M.273, L.284, Q.285, S.287, F.288
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:L.196, A:L.235, A:F.256, A:F.288, A:F.288, A:F.288
- Hydrogen bonds: A:Y.81, A:L.235, A:D.237, A:Q.238, A:Q.238, A:Y.253, A:Q.285, A:Q.285
- Water bridges: A:D.237
1L6.6: 14 residues within 4Å:- Chain B: Y.81, H.82, L.235, D.237, Q.238, I.248, I.252, Y.253, F.256, M.273, L.284, Q.285, F.288, I.292
10 PLIP interactions:10 interactions with chain B- Hydrophobic interactions: B:L.235, B:F.256, B:F.288, B:F.288, B:I.292
- Hydrogen bonds: B:L.235, B:Q.238, B:Q.285, B:Q.285
- Water bridges: B:D.237
1L6.9: 14 residues within 4Å:- Chain B: Q.17
- Chain C: Y.81, H.82, L.196, D.234, L.235, D.237, Q.238, I.248, I.252, F.256, M.273, S.287, F.288
10 PLIP interactions:1 interactions with chain B, 9 interactions with chain C- Hydrogen bonds: B:Q.17, C:L.235, C:Q.238
- Hydrophobic interactions: C:L.196, C:L.196, C:L.235, C:F.288
- Water bridges: C:D.237, C:Q.285, C:Q.285
1L6.12: 12 residues within 4Å:- Chain D: Y.81, H.82, L.196, L.235, D.237, Q.238, I.248, I.252, F.256, M.273, S.287, F.288
12 PLIP interactions:12 interactions with chain D- Hydrophobic interactions: D:L.196, D:L.235, D:F.288, D:F.288
- Hydrogen bonds: D:Y.81, D:L.235, D:D.237, D:Q.238
- Water bridges: D:D.237, D:Q.285, D:Q.285, D:Q.285
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Plummer, M.S. et al., Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. Bioorg.Med.Chem.Lett. (2013)
- Release Date
- 2013-05-01
- Peptides
- cGMP-dependent 3',5'-cyclic phosphodiesterase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.72 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x ZN: ZINC ION(Non-covalent)
- 4 x MG: MAGNESIUM ION(Non-covalent)
- 4 x 1L6: 1-(2-hydroxyethyl)-3-(2-methylbutan-2-yl)-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(1H)-one(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Plummer, M.S. et al., Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. Bioorg.Med.Chem.Lett. (2013)
- Release Date
- 2013-05-01
- Peptides
- cGMP-dependent 3',5'-cyclic phosphodiesterase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D